Aim Clinical trials have demonstrated the efficacy of the tetravalent human papillomavirus
(HPV) vaccination in the prevention of cervical cancer and genital warts associated with …

Objective: Based on positive safety and efficacy data, a quadrivalent Human PapillomaVirus
(HPV) vaccine has been approved in Switzerland to prevent HPV types 6, 11, 16 and 18 …

We evaluated the cost‐effectiveness of HPV16/18 vaccination for girls aged 12 years in The
Netherlands in addition to cervical cancer screening. For this purpose, we developed a …

Introduction Vaccination against human papillomavirus (HPV) is considered the most
effective strategy to protect women from cervical cancer. Three HPV vaccines are currently …

BACKGROUND: The use of human papillomavirus (HPV) vaccines has been universally
approved for women from age 12 to 25 years, but those older than 16 years receive no …

Background: The introduction of a quadrivalent human papillomavirus (HPV; types 6, 11, 16,
18) vaccine is expected to significantly reduce the burden of cervical cancer, cervical …

Cervical cancer is one of the most prevalent cancers among women worldwide.
Implementation of an HPV-vaccination strategy targeting the major oncogenic types 16 and …

Background The aim of this study was to assess the cost-effectiveness of human
papillomavirus (HPV) vaccination in addition to the current cervical cancer screening …

Objectives: The cost-effectiveness of adding a human papillomavirus (HPV) vaccination
program in 12-year-old females to the recommended cervical cancer screening in Belgium …

OBJECTIVE: The study predicts long-term cervical cancer related population health and
economic effects of introducing the HPV-vaccination for 12-year-old girls (and boys) in …